CPT code 95939 represents a central motor evoked potential (cMEP) study of the upper and lower limbs, used diagnostically for multiple sclerosis and as a prognostic tool for motor recovery after stroke. This neurophysiology diagnostic procedure is clinically important for care planning, prognosis, and specialized neurologic assessment, with implications for inpatient and outpatient neurology services nationwide. Key national payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, typical sites of service, common modifiers and coding considerations, and payer coverage patterns. The publication summarizes benchmarks and reimbursement context where available, highlights policy updates that affect coding and payment, and explains how the procedure integrates into stroke and multiple sclerosis care pathways. The report is intended for billing managers, neurology clinicians, and policy analysts seeking a focused reference on coding, clinical application, and payer handling of CPT code 95939. Data not available in the input is identified where applicable.